Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
66 hedge funds and large institutions have $18.3M invested in Asterias Biotherapeutics Inc. Series A in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
20% more funds holding
Funds holding: 55 → 66 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less capital invested
Capital invested by funds: $21.2M → $18.3M (-$2.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$7.44M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.13M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.12M |
| 4 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$364K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$234K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$485K |
| 2 |
ST
Spot Trading
Chicago,
Illinois
|
-$47.6K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$28.5K |
| 4 |
Citigroup
New York
|
-$27.1K |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| – | -$3K | -742 | Closed |
|
|
EDRH
52
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$3K | -625 | Closed |
|
|
TCM
53
Tradewinds Capital Management
Bellingham,
Washington
| – | +$7 | +2 | New |
|
|
GWS
54
Glassman Wealth Services
Vienna,
Virginia
| – | +$14 | +4 | New |
|
|
AG
55
Advisor Group
Phoenix,
Arizona
| – | +$398 | +110 | New |
|
|
FANJ
56
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | +$434 | +120 | New |
|
AST Hedge Fund Activity: Q2 2016 in Review
66 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q2 2016, worth a combined $18.3M — down 14% from $21.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AST positions and 5 closed out — a net gain of 11 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $7.44M. The largest seller was Fidelity Investments, cutting an estimated $485K.
- 66 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q2 2016, up from 55 in Q1 2016.
- Funds reported $18.3M of Asterias Biotherapeutics Inc. Series A stock for Q2 2016, down 14% quarter-over-quarter.
- 16 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q2 2016 and 5 closed out, a net change of +11 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q2 2016 was Broadwood Capital, an estimated $7.44M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q2 2016 was Fidelity Investments, an estimated $485K sold.
Based on aggregated 13F filings for Q2 2016.